MoonLake Immunotherapeutics Plummets 85% Following Disappointing Phase 3 Trial Results and Analyst Downgrades

Shares of MoonLake Immunotherapeutics are experiencing a dramatic pre-market plunge of 84.67% on Monday, following the release of disappointing results from its Phase 3 clinical trials and subsequent analyst downgrades.

The company announced the week 16 results of its Phase 3 VELA-1 and VELA-2 trials, which are part of its registrational global program. While specific details were not provided in the news summary, the market reaction suggests that the results fell short of expectations, triggering a wave of negative sentiment among investors and analysts alike.

In response to the trial results, multiple Wall Street firms have downgraded MoonLake Immunotherapeutics. RBC Capital analyst Brian Abrahams downgraded the stock to a Hold rating and slashed the price target from $67 to $10. Similarly, Stifel analyst Alex Thompson downgraded MLTX to Hold from Buy, reducing the price target to $13 from $77. These significant downgrades and price target cuts reflect a drastically altered outlook for the company's prospects, contributing to the severe pre-market sell-off.